Westchester Medical Center, New York Medical College, Westchester, New York, USA.
Curr Opin Organ Transplant. 2022 Feb 1;27(1):64-69. doi: 10.1097/MOT.0000000000000949.
The aim of this study was to describe recent developments in renal transplantation for HIV-positive recipients, especially the HIV Organ Policy Equity (HOPE) trial results.
HOPE trial data show that HIV-positive D+/R+ results are excellent and similar to D-/R+ in patients controlled on antiretroviral therapy (ART). Patients coinfected with hepatitis C or B virus now have effective treatment available. As pretransplant evaluation and post-transplant management is more complex in HIV-positive individuals early referral is important and coordination of evaluation and care with an infectious disease specialist is critical. HIV coordinated care services should be involved for best outcomes. HIV-positive renal transplant recipients have an increased risk of rejection and evidence suggests that standard lymphocyte depletion induction and maintenance immunosuppression be employed. Cardiovascular risk reduction and surveillance and attention to metabolic bone disease are important for HIV-positive renal transplant recipients.
HIV-positive to HIV-positive renal transplantation has been established as well tolerated and successful. Further efforts are needed to expand access to transplantation in this population.
本研究旨在描述 HIV 阳性受者肾移植的最新进展,特别是 HIV 器官政策公平(HOPE)试验结果。
HOPE 试验数据显示,在接受抗逆转录病毒治疗(ART)的患者中,HIV 阳性 D+/R+结果良好且与 D-/R+相似。同时合并丙型或乙型肝炎病毒感染的患者现在有有效的治疗方法。由于 HIV 阳性个体的移植前评估和移植后管理更为复杂,因此早期转介非常重要,并且需要与传染病专家协调评估和护理。为了获得最佳结果,应提供 HIV 协调护理服务。HIV 阳性肾移植受者的排斥风险增加,有证据表明应采用标准的淋巴细胞耗竭诱导和维持免疫抑制。减少心血管风险以及监测和关注代谢性骨病对 HIV 阳性肾移植受者非常重要。
HIV 阳性对 HIV 阳性肾移植已被证明是耐受良好且成功的。需要进一步努力扩大该人群的移植机会。